Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 848042, 10 pages
http://dx.doi.org/10.1155/2012/848042
Research Article

Identification of HLA-A24-Restricted Novel T Cell Epitope Peptides Derived from P-Cadherin and Kinesin Family Member 20A

1Second Department of Surgery, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-8510, Japan
2OncoTherapy Science Inc. Research Department, Kanagawa 213-0012, Japan
3Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan
4Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan

Received 6 February 2012; Revised 9 April 2012; Accepted 9 April 2012

Academic Editor: Soldano Ferrone

Copyright © 2012 Ryuji Osawa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We here identified human leukocyte antigen-(HLA-) A 2402-restricted epitope peptides from Cadherin 3, type 1, P-cadherin (CDH3) and kinesin family member 20A (KIF20A) that were found to be specifically expressed in cancer cells through genome-wide expression profile analysis. CDH3-10-807 peptide and KIF20A-10-66 peptide successfully induced specific CTL clones, and these selectively responded to COS7 cells expressing both HLA- A 2402 and respective protein while did not respond to parental cells or COS7 cells expressing either HLA- A 2402 or respective protein. Furthermore, CTL clones responded to cancer cells that endogenously express HLA- A 2402 and respective protein, suggesting that CDH3-10-807 peptide and KIF20A-10-66 peptide are naturally presented on HLA- A 2402 molecule of human cancer cells. Our results demonstrated that CDH3-10-807 peptide and KIF20A-10-66 peptide are novel HLA-A24-restricted tumor-associated antigens and would be applicable for CTL-inducing cancer therapies.